USTR Special 301 Report
By Dannemann Siemsen

The 2024 Special 301 Report from the Office of the United States Trade Representative (USTR) indicates significant delays within the Brazilian patent system, with average processing times approaching seven years for most applications and exceeding nine years for pharmaceutical patents. These prolonged timelines not only diminish the effective life of patents but may also contribute to considerable delays in market entry.
Although the Brazilian PTO has changed its patent examination practices and the patent backlog has decreased significantly, it seems that some stakeholders believe that there is still room for improvement.
Fortunately, Brazil does provide fast-track examination pathways that can significantly expedite processing for important applications.
While the overall backlog poses a challenge, proactive strategic planning can help mitigate these risks. Our team has extensive experience in identifying cases suitable for expedited processing and in navigating the requirements of these alternative pathways.
Additionally, the report raises concerns about inadequate protection against the unfair commercial use of undisclosed test data, a particularly pressing issue for pharmaceutical companies.
These updates can potentially impact on companies IP portfolio and demands a review in current strategies and explore options for optimizing IP protection in Brazil.